Corporate Profile & Recent News

An organization
designed to innovate

ElevateBio, LLC, is a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies. It begins with an environment where scientific inventors can transform their visions for cell and gene therapies into reality for patients with devastating and life-threatening diseases. Working with leading academic researchers, medical centers, and corporate partners, ElevateBio’s team of scientists, drug developers, and company builders are creating a portfolio of therapeutics companies that are changing the face of cell and gene therapy and regenerative medicine.

Core to ElevateBio’s vision is BaseCamp, a centralized state-of-the-art innovation and manufacturing center, providing fully integrated capabilities, including basic and transitional research, process development, clinical development, cGMP manufacturing, and regulatory affairs across multiple cell and gene therapy and regenerative medicine technology platforms. ElevateBio portfolio companies, as well as select strategic partners are supported by ElevateBio BaseCamp in the advancement of novel cell and gene therapies.

News

& Media

Stay up to date with news from our research, process development, cGMP manufacturing, clinical development, regulatory affairs, and commercial operations.

Webcast Event

Piper Sandler 32nd Annual Virtual Healthcare Conference
read more

November 23, 2020

ElevateBio to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
read more

November 16, 2020

ElevateBio and AgBiome Announce LifeEDIT Will Join ElevateBio’s Portfolio of Innovative Cell and Gene Therapy Companies
read more

Webcast Event

Morgan Stanley 18th Annual Global Healthcare Conference
read more

August 25, 2020

ElevateBio to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
read more

May 26, 2020

ElevateBio to Present at the Jefferies Virtual Healthcare Conference
read more

March 30, 2020

ElevateBio Closes $170 Million Series B Financing
read more

March 26, 2020

European Medicines Agency Grants Orphan Drug Designation to AlloVir’s Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy
read more

March 23, 2020

AlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell Therapies for COVID-19
read more

March 5, 2020

ElevateBio Appoints Kareem Reda as Chief Business Officer
read more

February 19, 2020

AlloVir to Present at the SVB Leerink 9th Annual Global Healthcare Conference
read more

February 12, 2020

AlloVir Receives the European Medicines Agency PRIME Designation for Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy
read more

December 9, 2019

ElevateBio Appoints Melissa K. Carpenter, Ph.D., as Chief Scientific Officer of Regenerative Medicine
read more

October 1, 2019

ElevateBio Launches HighPassBio to Advance Novel Targeted T Cell Immunotherapies with Technology from Fred Hutchinson Cancer Research
read more

September 10, 2019

Phase I Study of “Off-The-Shelf” Virus-Specific T Cells Published in BLOOD ADVANCES
read more

July 25, 2019

Massachusetts General Hospital and ElevateBio Announce a 10-Year Alliance Agreement to Utilize ElevateBio BaseCamp to Manufacture Innovative Cell and Gene Therapies
read more

June 11, 2019

AlloVir Announces Viralym-M Granted Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Hemorrhagic Cystitis Caused by BK Virus in Adults and Children Following Allogeneic HSCT
read more

May 22, 2019

ElevateBio announces that allovir joins its portfolio of highly innovative cell and gene therapy companies
read more

May 13, 2019

ElevateBio Launches to Create and Operate a Portfolio of Highly Innovative Cell and Gene Therapy Companies
read more

Executive Leaders and Co-Founders

Led and advised by a team of world-class biotech industry experts with unmatched track records in building iconic companies and creating value in the field of rare disease and cell and gene therapy
DAVID HALLAL
CEO & CHAIRMAN

David Hallal, Chairman and CEO of ElevateBio, is a 30-year veteran in the biopharmaceutical industry, with expertise in early-stage company building as well as operating large multinational biotech companies. He also is Chairman and CEO of AlloVir, an ElevateBio portfolio company.

MITCHELL FINER, PH.D.,
CHIEF SCIENTIFIC OFFICER

Dr.Mitchell (Mitch) Finer, Chief Scientific Officer of ElevateBio, has been instrumental in founding, building and leading a number of MPM portfolio companies. Mitch serves on several MPM portfolio company boards, including CODA, Oncorus, Semma Therapeutics and TCR2 Therapeutics.

vikas sinha
Chief financial officer

Vikas Sinha, CFO of ElevateBio, has more than 25 years of experience in executive finance roles in the life sciences industry. He previously served as the CFO of Alexion Pharmaceuticals. During his tenure as CFO, Alexion’s market cap grew from $600 million to more than $30 billion and revenue grew from zero to more than $3 billion.

Board of Directors

David Hallal, Co-Founder Chief Executive Officer & Chairman, ElevateBio
Mitchell Finer, Ph.D., Chief Scientific Officer
Vikas Sinha, Chief Financial Officer
Ansbert Gadicke, M.D. co-founder of MPM Capital
Morana Jovan-Embiricos, Ph.D., Managing Partner of F2 Ventures
Germano Giuliani, Former CEO, Giuliani Pharma; Board of Directors, HBM Healthcare AH; Investment Committee Royalty Pharma

Investors committed to enabling
innovative cell and gene therapy companies

Ready to acclerate your innovation? Connect with our business development team and learn more.
connect